About mb software - SMTI
Sanara MedTech, Inc. engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.
SMTI At a Glance
Sanara MedTech, Inc.
1200 Summit Avenue
Fort Worth, Texas 76102
| Phone | 1-817-529-2300 | Revenue | 103.12M | |
| Industry | Medical Specialties | Net Income | -37,562,606.00 | |
| Sector | Health Technology | 2025 Sales Growth | 18.974% | |
| Fiscal Year-end | 12 / 2026 | Employees | 108 | |
| View SEC Filings |
SMTI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.953 |
| Price to Book Ratio | 35.179 |
| Price to Cash Flow Ratio | 29.67 |
| Enterprise Value to EBITDA | 19.729 |
| Enterprise Value to Sales | 2.259 |
| Total Debt to Enterprise Value | 0.207 |
SMTI Efficiency
| Revenue/Employee | 954,796.13 |
| Income Per Employee | -347,801.907 |
| Receivables Turnover | 8.595 |
| Total Asset Turnover | 1.281 |
SMTI Liquidity
| Current Ratio | 1.801 |
| Quick Ratio | 1.589 |
| Cash Ratio | 0.89 |
SMTI Profitability
| Gross Margin | 90.125 |
| Operating Margin | 8.869 |
| Pretax Margin | -0.381 |
| Net Margin | -36.427 |
| Return on Assets | -0.481 |
| Return on Equity | -1.71 |
| Return on Total Capital | -0.716 |
| Return on Invested Capital | -0.62 |
SMTI Capital Structure
| Total Debt to Total Equity | 811.541 |
| Total Debt to Total Capital | 89.03 |
| Total Debt to Total Assets | 66.068 |
| Long-Term Debt to Equity | 805.592 |
| Long-Term Debt to Total Capital | 88.377 |